Autumn Glory Partners LLC purchased a new position in shares of Becton, Dickinson and Company (NYSE: BDX – Get Rating) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 9,048 shares of the medical instruments supplier’s stock, valued at approximately $ 2,274,000.
A number of other large investors also recently made changes to their positions in BDX. Diamond Hill Capital Management Inc. acquired a new position in Becton, Dickinson and in the fourth quarter valued at $ 395,149,000. Morgan Stanley increased its stake in shares of Becton, Dickinson and by 16.9% during the second quarter. Morgan Stanley now owns 9,175,000 shares of the medical instruments supplier’s stock worth $ 2,231,268,000 after acquiring an additional 1,323,224 shares during the period. Wellington Management Group LLP increased its stake in shares of Becton, Dickinson and by 6.1% during the third quarter. Wellington Management Group LLP now owns 14,489,749 shares of the medical instruments supplier’s stock worth $ 3,561,871,000 after acquiring an additional 837,802 shares during the period. Invesco Ltd. increased its stake in shares of Becton, Dickinson and by 19.6% during the fourth quarter. Invesco Ltd. now owns 3,075,333 shares of the medical instruments supplier’s stock worth $ 773,385,000 after acquiring an additional 504,932 shares during the period. Finally, State Street Corp increased its stake in shares of Becton, Dickinson and by 3.9% during the fourth quarter. State Street Corp now owns 12,705,205 shares of the medical instruments supplier’s stock worth $ 3,195,105,000 after acquiring an additional 480,684 shares during the period. Hedge funds and other institutional investors own 86.58% of the company stock.
In related news, EVP David Hickey sold 475 shares of the company stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $ 256.00, for a total transaction of $ 121,600.00. Following the completion of the transaction, the executive vice president now owns 3,806 shares of the company stock, valued at $ 974,336. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Thomas J. Spoerel sold 443 shares of the company stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $ 260.00, for a total transaction of $ 115,180.00. Following the transaction, the vice president now directly owns 1,058 shares of the company stock, valued at approximately $ 275,080. The disclosure for this sale can be found here. Corporate insiders own 0.50% of the company stock.
A number of research analysts have recently issued reports on the stock. Morgan Stanley boosted their price target on shares of Becton, Dickinson and from $ 293.00 to $ 295.00 and gave the stock an “overweight” rating in a research note on Monday, April 11th. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and from $ 275.00 to $ 285.00 and gave the stock an “equal weight” rating in a research note on Friday, April 1st. Piper Sandler decreased their price objective on shares of Becton, Dickinson and from $ 265.00 to $ 255.00 in a report on Thursday, May 5th. StockNews.com downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Argus boosted their price target on shares of Becton, Dickinson and from $ 275.00 to $ 310.00 in a report on Monday, February 28th. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $ 280.83.
Shares of NYSE BDX opened at $ 236.32 on Wednesday. Becton, Dickinson and Company has a 12-month low of $ 233.05 and a 12-month high of $ 280.62. The company has a market capitalization of $ 67.37 billion, a PE ratio of 37.27, a price-to-earnings-growth ratio of 3.37 and a beta of 0.64. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. The firm’s 50-day moving average is $ 256.45 and its two-hundred day moving average is $ 258.55.
Becton, Dickinson and (NYSE: BDX – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $ 3.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $ 2.98 by $ 0.20. The business had revenue of $ 5.01 billion for the quarter, compared to the consensus estimate of $ 4.78 billion. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The company quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $ 3.19 earnings per share. On average, analysts forecast that Becton, Dickinson and Company will post 11.2 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 9th will be paid a dividend of $ 0.87 per share. This represents a $ 3.48 annualized dividend and a dividend yield of 1.47%. The ex-dividend date of this dividend is Wednesday, June 8th. Becton, Dickinson and’s payout ratio is 54.89%.
Becton, Dickinson and Profile: (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Featured Stories:
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE: BDX – Get Rating).
Receive News & Ratings for Becton Dickinson and Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and and related companies with MarketBeat.com’s FREE daily email newsletter.
.